• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Bye-Bye China?

    Decentralized Trials Fuel AI Revolution in Clinical Research

    Self-Medication: Flexibility for Patients and Drug Manufacturers

    The Single-Use Mixing Landscape: Evaluating Your Options

    DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    WDSrx Expands Warehouse Network

    Piramal Inks Clinical Supply Deal with Theratechnologies

    Recipharm Signs Manufacturing Deal with Enzymatica

    CDMO Northway Biotech Expands in U.S.

    Lonza to Exit Pharma Softgels and Liquid-Filled Hard Capsules
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    WDSrx Expands Warehouse Network

    Catalent Acquires Acorda’s INBRIJA Manufacturing Operations

    Varcode, PL Developments Form Strategic ‘Smart Tag’ Pact

    COVID-19 Vaccine Distribution: The Air Cargo Industry’s Greatest Challenge

    Thermo Fisher Expands Clinical Supply Services in Europe
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Improving Product Profitability

    CDMO Northway Biotech Expands in U.S.

    Global Biosciences Co. Selects ValGenesis VLMS

    Nexelis Acquires GSK Vax Lab in Marburg

    The Future of Clinical Trials Series: Part I
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Samsung Biologics Adopts Veeva Vault QMS to Unify Quality Management

    CDMO Cognate BioServices Teams Up with L7 Informatics
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Syngene

    Cytovance Biologics

    Aphena Pharma Solutions

    Reed-Lane

    PCI Pharma Services
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    PCI Pharma Services

    Flow Sciences

    Syngene

    Emergent BioSolutions

    Cytovance Biologics
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Columns

    Vision: 2020

    You have exactly 366 days in 2020 to bring your clarity of vision to reality.

    Vision: 2020
    Ben Locwin01.28.20
    As I write this, it is the 30th of December, 2019. As we ramp up for 2020, let’s remember that it’s a leap year. That extra day gives us about 1/1,300th of an additional year’s worth of time to make things count this year. How best to not squander our time? Develop plans for your strategic approaches for the new year. Keep yourself honest by devising metrics that will indicate if you are on-track or off-track through frequent check-ins with your plan throughout the year.

    Plan for Success
    In the planning world, there are lots of opinions, and most are wrong. But probably the most correct one is my favorite of Dwight Eisenhower’s quote, “The plan is nothing. Planning is everything.” Many groups whom I’ve discussed this with have an incorrect or inadequate appraisal of the content of this quote. Where the value actually lies in this quote is the lexical play of the noun versus the verb usage in the quote. The “plan” as Eisenhower referred to it is the paper-and-pencil document (the noun) that is the output of the verb of “planning.” Holding in your hand a ‘plan’ for what your organization should be doing is the component which is nearly useless. As soon as the group adjourns, and even before the ink is dry (only an analogy if it’s actually written in pencil or printed via laser printer), it is aging. That’s right: The fruits of your planning, which exist in this written document, are aging day-by-day, and most likely, they’re aging in a way that makes them more and more inaccurate. This is due simply to stochasticity in the external environment in which you work and the financial markets which are at play. This is simple economics fact.


    "Plans are nothing; planning is everything."
    —Dwight Eisenhower

    However, the activity which led to the document is one in which success lies. The activity (verb) of planning is what gets your teams to sit around and discuss latent and emerging issues, risks, to conterintuit, to play ‘what-if’ scenarios, to look at unintended consequences. The amount of ‘future histories’ which can come out of this are essentially infinite, but very much bounded by the practical experience of those who you involved in the process. Groups who operate like this, and can avoid the negative and dysplastic elements of groupthink tend to outperform every other method of forecasting that’s currently available. And that includes most types of Machine Learning which currently exist.

    The Market In Some Sense Drives The Industry
    What I mean by this is the Financial Markets, whose overall impact to the drug development lifecycle can neither be understated nor underestimated. When boundary-breaking therapies come up upon our current horizon through which they will, by definition, break, the financial markets take notice. That is because behind each is a potential economic windfall, not only for that current therapeutic modality or idea, but for all of the technological advancements it undoubtedly represents and ushers in with it. Every single new groundbreaking type of drug (and medtech) therapy has created new approaches to thinking about disease and disease management, as well as approaches to supply chain, patient communication, drug safety reporting, and so on. The markets are to some degree sensitive to this, even if they’re not aware of it fully (to anthropomorphize the markets into an entity, anyway). The economics of this situation drives innovation, R&D spend, regulatory approval approaches, and basically reshapes the entire industry. These cycles have been occurring in intervals of about 4-9 years, but are themselves shaped or assisted by additional changes which derive from changes to regulations and regulatory guidances, such as new revisions to FDA’s Code of Federal Regulations Title 21 (CFR) and the International Council for Harmonisation’s ([…of Technical Requirements for Pharmaceuticals for Human Use], i.e., ICH) semi-frequent updates.

    On the Horizon – Scenario Planning
    Forecasting for the year 2020, and hopefully with visual acuity also of 20/20, is a very difficult endeavor.

    Cell Therapy and Gene Therapy
    Cell therapies and gene therapies will continue to rise, tempered by safety and efficacy empiricity—how the data actually look from the clinical trials—and the public’s ever-fickle tolerance for innovation and risk versus benefit.

    Manufacturing
    Manufacturing will continue to drive to outsourcing and CRO/CDMO/CMO
    offerings, which gives smaller startups the ability to innovate with venture capital, and not have to be disintegrated by the burdens of manufacturability overhead. We’ve seen in 2019 that cell therapies have presented some novel and potentially nuanced challenges with respect to manufacturing, and so solving these modern challenges will continue in 2020. These are problems that we didn’t fully predict in the past, and to paraphrase Albert Einstein, “the significant problems we face (now) cannot be solved at the same level of thinking that we were at when we created them.” We create a new future, one in which we now all reside, and the associated problems that came with it are where we have to dedicate our resources to respond to next.

    Expansion or Contraction of the Anti-Vax(?)
    The past decade has brought with it an almost unheard-of level of scrutiny and rejection of basic scientific principles. Among them, people around the world have been so successfully healthy with our current medical treatments, that they had started, inexplicably, to reject the very immunizations that have led to the reduction or elimination of so many terrible diseases. I’ve seen some conflicting signals here: On one hand, the anti-vaxxers are operating as vociferously and science-rejectiony as ever, but now, very interestingly and paradoxically, those who are interested in fact-based opinions are becoming more vocal, and there seems to be signals in the data suggesting younger people at the moment—younger than the anti-vaxxer demographic, which used to represent a younger cohort in society than the general public of vaccine-adherents—are rejecting the anti-vaxxers nonscientific propaganda, and attempting to support the notions of vaccines and herd immunity.

    How I read this signal is that it’s a retrocycle reminiscent of how rejection of smoking came as a result largely attributable to younger generations rebelling against those things that their parents found to be fashionable or signs of the times. These retrocycles and their associated tipping points are hard to pin down, except in hindsight. So I’ll leave this one optimistically as suggesting that anti-vaxxers will lose overall ground in 2020. With big confidence intervals. I think this view is optimistic both for the charge of science, as well as for the health of the population, where vaccines for measles, mumps, rubella, tetanus, polio, diphtheria, influenza and human papillomavirus are available widely and have demonstrated incredible successes and safety.

    Even on the ebola front, there has been a flurry of activity which has led to a predominately-effective immunization, however caution is warranted because the overall sample size totals within which it’s been trialled have been relatively small.

    In addition, the idea of a ‘universal’ flu vaccine has also gotten a bit more traction lately. It used to be that in the vaccine circles which I would frequent, the colloquialism was that a universal flu vaccine would be available “in 5 to 10 years,” which was understood industry code for a moving time horizon (that was moving faster forward than actual time) which meant, in effect, “never.”

    To develop a universal flu vaccine requires that certain aspects of the virology of influenzaviridae, which are less likely to genetically shift and drift are the ones used in development of the immunization. This would confer protection, then, against a very broad range of influenza types and subtypes, without having to worry about yearly re-immunizations. There are also those who have been worried about exposure to RNA fragments in vaccines and adjuvants, so to reduce the overall number of immunizations required would be welcome by the public.

    What you can do in 2020
    First, for your work within your organizations, if you jumped right to this conclusion in the article, go back up to the ‘Plan for Success’ section and read that first. It will lead to tremendous opportunities for process and programmatic improvements.

    If there’s anything we can all do as an industry together, to move our interests forward, support each other, and help humanity in the process, it’s to bring back science to the public’s vernacular. Real, verifiable, empirical science. Educating friends, neighbors, and the public that what they usually read about healthcare and medical treatments and pharmaceuticals is almost exactly wrong. By bringing this clarified lens of objectivity to discussion not only could help teach many in the public where they can seek out relevant and factual information to help maintain or improve their overall health, but the same approaches can also help sharpen your internal organizational meetings. Opinions and ‘gut feel’ can be just as wrong as right (or more so) and their effects can go unnoticed until they’ve caused a lot of unmitigated damage. Plan (as a verb), refine your plan with fresh data as often as possible, ask others to do the same, and cut away activities that are robbing you of your time and productivity where it really matters. 


    Ben Locwin

    Ben Locwin is an author, a speaker, and advises on future forecasts for pharmaceuticals, medical devices, and healthcare policy. He is an ardent philanthropist for technologies and causes which benefit health outcomes, and participates on a variety of advisory boards.
    Related Searches
    • CDMO
    • cell therapies
    • expansion
    • machine learning

    Related Columns

    • A Potential “Marriage”

      A Potential “Marriage”

      Initiator companies and generics/CMOs working together.
      Emil W. Ciurczak, DoraMaxx Consulting 11.17.20

    • When Politics and Science Collide

      When Politics and Science Collide

      COVID-19 illustrates why science should always be a principal informer of politics to make better and smarter decisions.
      Ben Locwin, Contributing Editor 11.17.20

    • The Pandemic’s Become an Insurmountable Opportunity

      The Pandemic’s Become an Insurmountable Opportunity

      Every Cloud has a Silver Lining(?)
      Emil W. Ciurczak, Contributing Editor 10.14.20


    • Biologics, Proteins, Vaccines
      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      It Takes a Vaccine… To End The Pandemic [У нас есть хорошая вакцина]

      Race for the vaccines is heating up.
      Ben Locwin, Contributing Editor 09.09.20

    • cGMP Manufacture
      Keys to Biotech Success

      Keys to Biotech Success

      Four steps emerging biotech companies can take to achieve success
      Thierry Cournez, Head of End-to-End Solutions, MilliporeSigma 06.04.20

    • Analytical Services
      What Happens When the All-Clear Signal is Given?

      What Happens When the All-Clear Signal is Given?

      Maybe 3M had some good ideas?
      Emil W. Ciurczak, DoraMaxx Consulting 06.04.20


    • Almost Like the Olympics:

      Almost Like the Olympics:

      “Smaller, Faster, Smarter”
      Emil W. Ciurczak, DoraMaxx Consulting 05.05.20

    • Rapid Delivery of Medical Countermeasures Amid Pandemic

      Rapid Delivery of Medical Countermeasures Amid Pandemic

      Robert Erwin of iBio discusses the company’s COVID-19 vaccine development efforts and FastPharming manufacturing platform for the rapid delivery of vaccines
      Kristin Brooks, Managing Editor, Contract Pharma 05.05.20

    • The Supply Chain House of Cards

      The Supply Chain House of Cards

      The COVID-19 pandemic exposes pressures on extended global supply chains
      Emil W. Ciurczak, DoraMaxx Consulting 04.01.20


    • Analytical Services | Laboratory Testing
      The Supply Chain, as Developed by IKEA (some assembly required)

      The Supply Chain, as Developed by IKEA (some assembly required)

      Pick One from Column A, Two from Column B, etc.
      Emil W. Ciurczak, DoraMaxx Consulting 03.04.20

    • Coronavirus 2020

      Coronavirus 2020

      What’s The Impact To The World and Industry?
      Ben Locwin, Contributing Editor 03.04.20

    • Supply Chain
      What We Have is Failure to Communicate

      What We Have is Failure to Communicate

      When it comes to implementing track and trace technology, why is Pharma dragging its feet?
      Emil W. Ciurczak, DoraMaxx Consulting 01.28.20


    • Solid Dosage/Creams/Ointments
      The “Greening” of Solid Dosage Form Manufacturing

      The “Greening” of Solid Dosage Form Manufacturing

      Going “green” can mean saving big bucks for pharma manufacturers.
      Emil W. Ciurczak, DoraMaxx Consulting 11.20.19

    • When Life Gives You Lemons…Raise Your Drug Prices

      When Life Gives You Lemons…Raise Your Drug Prices

      The hidden effect of economic models on global drug supply and shortages.
      Ben Locwin 11.20.19

    • Like It’s 1999

      Like It’s 1999

      Reflecting on 20 years of Contract Pharma.
      Gil Roth, President, Pharma & Biopharma Outsourcing Association 10.15.19

    Trending
    • Lonza To Exit Pharma Softgels And Liquid-Filled Hard Capsules
    • The Future Of Clinical Trials Series: Part I
    • Grifols Begins COVID-19 Plasma Treatment Trial
    • Thermo Fisher Buys Novasep's Viral Vector Manufacturing Biz
    • NovaQuest Private Equity Acquires CoreRx
    Breaking News
    • WDSrx Expands Warehouse Network
    • Piramal Inks Clinical Supply Deal with Theratechnologies
    • Recipharm Signs Manufacturing Deal with Enzymatica
    • CDMO Northway Biotech Expands in U.S.
    • Global Biosciences Co. Selects ValGenesis VLMS
    View Breaking News >
    CURRENT ISSUE

    November/December 2020

    • Modeling Process Safety Workflows in Pharmaceutical Manufacturing Scale-Up
    • Ensuring Quality During the Transfer and Scale Up of Rx Drugs
    • Inspecting the Unexpected
    • Cold Chain Trends
    • Catering for the Complex
    • Biopharma Contract Manufacturing: Robust Growth Ahead
    • DCAT President Talks COVID-19, Drug Manufacturing and Innovation
    • The Single-Use Mixing Landscape: Evaluating Your Options
    • Self-Medication: Flexibility for Patients and Drug Manufacturers
    • Decentralized Trials Fuel AI Revolution in Clinical Research
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    NIH Study Compares Low-Fat, Plant-based to Low-Carb, Animal-Based Diet
    Gadot Positions Mineral Line for Vegan Market
    Nutritfy India to Launch Global Broadcast Channel Covering Nutrition
    Coatings World

    Latest Breaking News From Coatings World

    IGL Coatings Launches Graphene Reinforced Dual System Ceramic Coating
    Miller Paint Declares Simple Serenity its 2021 Color of the Year
    TAUBMANS Paint by PPG Releases ‘Chromatic Joy’ Palettes
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    TPI Partners with Zeiss
    PPE Moves into New Manufacturing Facility
    Neurent Medical Closes $25 Million Series B Financing
    Contract Pharma

    Latest Breaking News From Contract Pharma

    WDSrx Expands Warehouse Network
    Piramal Inks Clinical Supply Deal with Theratechnologies
    Recipharm Signs Manufacturing Deal with Enzymatica
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Lageen Tubes Launches Mono-Material PE Tube Solutions
    Jason Jones Loses Battle with Covid-19
    Weleda Celebrates 100 Years By 'Opening' Its Gardens
    Happi

    Latest Breaking News From Happi

    NY's 1,4-Dioxane Law May Impact Concentrated Cleaners
    Sabinsa's Top Scientist Addresses US FDA
    Ipsy Adds New Personal Care Brand
    Ink World

    Latest Breaking News From Ink World

    Morancé Soudure France Adds Comexi F2 MC 10-color Flexo Press
    THIMM Group Installs 1st Koenig & Bauer CorruFLEX
    Cowan Graphics Adds Fujifilm Inca OnsetX3 HS
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Lemu Group engineers mask-making machine
    Niagara Label upgrades with Nilpeter flexo press
    Soma partners with Moore & Moore in US
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Lemu Group Engineers Mask-Making Machine
    Armbrust American Adds Meltblown Manufacturing
    P&G Reports 8% Sales Increase
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Siemens Healthineers’ DR Systems Cleared by FDA
    Former Medtronic Exec Appointed Zimmer Biomet's Chief Transformation Officer
    SeaSpine Launches Regatta Lateral Plates
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    UDC Subsidiary Adesis' Website Wins 2020 MarCom Platinum Award
    Roadsimple Modernizes Warehouse Ops with Zebra Technologies
    Graphene Flagship Launches Redesigned Website

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login